Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177Lu-PRLT in earlier and later phases of mCRPC grouped by previous taxane chemotherapy. Methods: A retrospective analysis was performed on 167 patients with mCRPC who underwent 177Lu-PRLT between March 2013 and December 2016. Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naïve (T-naïve) depending on whether they had received taxane-based chemotherapy prior to 177Lu-PRLT. Clinical outcome for T-pretreated and T-naïve patients was assessed by overall survival (OS), radiographic progression-free survival, and prostate-specific antigen (PSA) response rate. Univariate and multivariable analyses were performed for both T-pretreated and T-naïve patients to determine predictors of outcome. Toxicity was categorized by the Common Terminology Criteria for Adverse Events (version 4.03). Results: Of the 167 patients treated with 177Lu-PRLT, 83 were T-pretreated and 84 were T-naïve. At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower hemoglobin levels, higher alkaline phosphatase (ALP) levels and had received more additional therapies compared with T-naïve patients. Median OS was 10.7 mo for T-pretreated patients and 27.1 mo for T-naïve patients. Median radiographic progression-free survival was 6.0 mo for T-pretreated patients and 8.8 mo for T-naïve patients. PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T-pretreated patients and 40 of 70 (57%) T-naïve patients. Significant determinates of inferior OS in multivariable analysis for T-pretreated patients were poorer performance status, lower cumulative administered activity, and lower baseline hemoglobin. Higher baseline alkaline phosphatase was the only significant determinate of inferior OS in multivariable analysis for T-naïve patients. Overall 177Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-naïve patients. Conclusion:177Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal associated toxicity seen in both our T-naïve and heavily pretreated patient cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“5 mo were seen in patients receiving docetaxel treatment regimens, resulting in a survival benefit of 2–3 months compared with other treatments (5,6).”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“OS with these agents as second-line therapies in selected patient cohorts ranges from 14 to 18 mo (4,8,9,11).”
BackgroundAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“OS with these agents as second-line therapies in selected patient cohorts ranges from 14 to 18 mo (4,8,9,11).”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · cited 1×
“OS with these agents as second-line therapies in selected patient cohorts ranges from 14 to 18 mo (4,8,9,11).”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Kirby, M., Hirst, C., & Crawford, E. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02799.x · Cited by 861 · cited 2×
“Although androgen deprivation therapy is effective in hormone-sensitive disease, 10%–20% of patients will eventually progress under castrate levels of testosterone (2).”
Background68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., Giesel, F., Haberkorn, U., Hope, T. A., Kopka, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3670-z · Cited by 750 · cited 1×
“Nevertheless, given that RECIST- and bone scan–based criteria have major limitations in assessing disease response in patients with extensive bone metastases, our results remain meaningful despite the absence of established clinical guidelines in this regard (31).”
ResultKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Cited by
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06255-8 · Cited by 299
Self-citationSathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210
Self-citationHummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Maurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1341 · Cited by 14
Metadata
- Authors
- Barber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., & Baum, R. P.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2019-01-25
- Volume
- 60
- Issue
- 7
- Pages
- 955-962
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2914833937
- Cited by
- 132
- References
- 10
- FWCI
- 12.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. https://app.cochat.ai/papers/10.2967/jnumed.118.216820
- The paper
- Barber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., & Baum, R. P. (2019). Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.118.216820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.